Neurodegenerative Disease News and Research

RSS

TSRI study shows how aging affects brain's neural circuitry

How aging affects communication between neurons is not well understood, a gap that makes it more difficult to treat a range of disorders, including Alzheimer's and Parkinson's disease.

23 Jan 2014

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

Researcher finds possible way to unravel misfolded proteins by reprogramming yeast protein

At the heart of brain diseases such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease is protein misfolding, in which distorted proteins are unable to perform their normal functions. At present, there is no known way to reverse protein misfolding.

17 Jan 2014

Parkinson's disease patients from lower socioeconomic status less likely to receive DBS

Among Parkinson's disease (PD) patients, female, black, Asian and patients are substantially less likely to receive proven deep brain stimulation (DBS) surgery to improve tremors and motor symptoms, according to a new report by a Perelman School of Medicine at the University of Pennsylvania researcher who identified considerable disparities among Medicare recipients receiving DBS for Parkinson's disease.

5 Jan 2014

Numotion partners with The ALS Association to support individuals affected by Lou Gehrig's Disease

Numotion, the complex wheelchair company committed to serving the lifelong needs of people through individualized health and mobility solutions, has partnered with The ALS Association to offer support and enhance the quality of life for individuals affected by amyotrophic lateral sclerosis (ALS).

3 Jan 2014

Nonsteroidal anti-inflammatory agent delays neuropathy progression, preserves quality of life

Among patients with familial amyloid polyneuropathy, a lethal, genetic neurodegenerative disease, use of the nonsteroidal anti-inflammatory agent diflunisal compared with placebo for 2 years reduced the rate of progression in neurological impairment and preserved quality of life, according to a study appearing in the December 25 issue of JAMA.

27 Dec 2013

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

18 Dec 2013

NUS scientists open possible new route for treatment of spinal muscular atrophy

A recent study led by scientists from the National University of Singapore (NUS) opens a possible new route for treatment of Spinal Muscular Atrophy (SMA), a devastating disease that is the most common genetic cause of infant death and also affects young adults.

18 Dec 2013

Research findings point to possible new strategy for treating ALS

Amyotrophic lateral sclerosis, better known as Lou Gehrig's disease, is a devastating illness that gradually robs sufferers of muscle strength and eventually causes a lethal, full-body paralysis. The only drug available to treat the disease extends life spans by a meager three months on average.

17 Dec 2013

Study: Brain blood vessel cells may be therapeutic targets for Alzheimer's disease

A study in mice shows how a breakdown of the brain's blood vessels may amplify or cause problems associated with Alzheimer's disease. The results published in Nature Communications suggest that blood vessel cells called pericytes may provide novel targets for treatments and diagnoses.

14 Dec 2013

Prana Biotechnology provides update on IMAGINE PBT2 trial for Alzheimer’s disease

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today provided an update of its IMAGINE Alzheimer’s Disease Extension trial.

11 Dec 2013

European study investigates high blood pressure drug for treating Alzheimer's patients

An extensive European study is currently investigating whether a drug used to treat high blood pressure may also help patients with Alzheimer's disease. The EU is investing almost 6 million euros on the project, in which Sahlgrenska Academy and Sahlgrenska University Hospital are responsible for Sweden's contribution.

10 Dec 2013

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

In mice with a rodent form of multiple sclerosis (MS), vitamin D appears to block damage-causing immune cells from migrating to the central nervous system, offering a potential explanation for why the so-called "sunshine vitamin" may prevent or ease symptoms of the neurodegenerative disease, according to results of a study at Johns Hopkins.

9 Dec 2013

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease clinical trial.

9 Dec 2013

Finding identifies new mechanism that could contribute to the pathology of ALS

RNA molecules, used by cells to make proteins, are generally thought to be "silent" when stowed in cytoplasmic granules. But a protein mutated in some ALS patients forms granules that permit translation of stored RNAs, according to a study in The Journal of Cell Biology. The finding identifies a new mechanism that could contribute to the pathology of the disease.

4 Dec 2013

Certain Chinese medicines can regulate neurotrophic and apoptosis-related factors

Parkinson's disease is a common neurodegenerative disease in the elderly, which is pathologically characterized by selective loss of dopaminergic neurons. Compound preparations of Chinese medicines that can tonify the kidney have been reported to significantly improve symptoms of Parkinson's disease.

28 Nov 2013

Compound extracted from wine-processed Fructus corni protects hippocampal neurons from damage

Studies have shown that Fructus corni has a protective effect on hepatocytes, and has anticancer, antioxidative, anti-inflammatory and antiseptic properties. 5-hydroxymethylfurfural, a compound extracted from wine-processed Fructus corni, has a protective effect on hippocampal neurons damaged by H2O2.

28 Nov 2013

Protecting or boosting neurotrophins may slow progression of Huntington's disease

A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.

27 Nov 2013

Neuroscientists discover new role played by common but mysterious class of brain cells

Stanford University School of Medicine neuroscientists have discovered a new role played by a common but mysterious class of brain cells.

26 Nov 2013

£20M research centre opened to investigate exciting new therapies for neurodegenerative diseases

A specialist £20 million research centre, funded by the Wolfson Foundation and dedicated to carrying out first-in-human studies, opens in London today (15th November). Researchers at the Leonard Wolfson Experimental Neurology Centre (LWENC) will investigate exciting new therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's.

16 Nov 2013